Ikena Oncology (IKNA) Competitors $1.31 -0.01 (-0.68%) As of 11:55 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock IKNA vs. IMMP, PRME, SLRN, ANNX, ITOS, CDTX, ACB, TSVT, CRDF, and OLMAShould you be buying Ikena Oncology stock or one of its competitors? The main competitors of Ikena Oncology include Immutep (IMMP), Prime Medicine (PRME), Acelyrin (SLRN), Annexon (ANNX), iTeos Therapeutics (ITOS), Cidara Therapeutics (CDTX), Aurora Cannabis (ACB), 2seventy bio (TSVT), Cardiff Oncology (CRDF), and Olema Pharmaceuticals (OLMA). These companies are all part of the "pharmaceutical products" industry. Ikena Oncology vs. Immutep Prime Medicine Acelyrin Annexon iTeos Therapeutics Cidara Therapeutics Aurora Cannabis 2seventy bio Cardiff Oncology Olema Pharmaceuticals Ikena Oncology (NASDAQ:IKNA) and Immutep (NASDAQ:IMMP) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, community ranking, dividends, risk, media sentiment, valuation, earnings, profitability and institutional ownership. Which has more volatility and risk, IKNA or IMMP? Ikena Oncology has a beta of 0.49, indicating that its share price is 51% less volatile than the S&P 500. Comparatively, Immutep has a beta of 2.34, indicating that its share price is 134% more volatile than the S&P 500. Do analysts prefer IKNA or IMMP? Ikena Oncology currently has a consensus price target of $3.00, suggesting a potential upside of 128.83%. Immutep has a consensus price target of $8.50, suggesting a potential upside of 355.76%. Given Immutep's stronger consensus rating and higher probable upside, analysts clearly believe Immutep is more favorable than Ikena Oncology.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ikena Oncology 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50Immutep 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is IKNA or IMMP more profitable? Immutep's return on equity of 0.00% beat Ikena Oncology's return on equity.Company Net Margins Return on Equity Return on Assets Ikena OncologyN/A -36.88% -33.08% Immutep N/A N/A N/A Does the media prefer IKNA or IMMP? In the previous week, Immutep had 1 more articles in the media than Ikena Oncology. MarketBeat recorded 2 mentions for Immutep and 1 mentions for Ikena Oncology. Ikena Oncology's average media sentiment score of 1.89 beat Immutep's score of 0.87 indicating that Ikena Oncology is being referred to more favorably in the media. Company Overall Sentiment Ikena Oncology Very Positive Immutep Positive Do institutionals and insiders believe in IKNA or IMMP? 75.0% of Ikena Oncology shares are owned by institutional investors. Comparatively, 2.3% of Immutep shares are owned by institutional investors. 5.9% of Ikena Oncology shares are owned by company insiders. Comparatively, 3.1% of Immutep shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Does the MarketBeat Community prefer IKNA or IMMP? Immutep received 282 more outperform votes than Ikena Oncology when rated by MarketBeat users. Likewise, 72.56% of users gave Immutep an outperform vote while only 58.82% of users gave Ikena Oncology an outperform vote. CompanyUnderperformOutperformIkena OncologyOutperform Votes3058.82% Underperform Votes2141.18% ImmutepOutperform Votes31272.56% Underperform Votes11827.44% Which has better earnings and valuation, IKNA or IMMP? Immutep has higher revenue and earnings than Ikena Oncology. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioIkena Oncology$659K96.00-$68.17M-$1.01-1.30Immutep$5.14M52.81-$28.01MN/AN/A SummaryImmutep beats Ikena Oncology on 11 of the 15 factors compared between the two stocks. Remove Ads Get Ikena Oncology News Delivered to You Automatically Sign up to receive the latest news and ratings for IKNA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IKNA vs. The Competition Export to ExcelMetricIkena OncologyBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$62.74M$2.98B$5.61B$7.68BDividend YieldN/A1.55%5.33%4.02%P/E Ratio-1.0630.5323.5018.55Price / Sales96.00413.42376.0088.66Price / CashN/A168.6838.1734.64Price / Book0.373.766.814.11Net Income-$68.17M-$71.95M$3.20B$247.18M7 Day Performance-5.68%-10.14%-5.42%-4.05%1 Month Performance-2.16%-15.29%-0.12%-6.41%1 Year Performance-7.68%-30.23%7.61%-2.08% Ikena Oncology Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IKNAIkena Oncology2.9249 of 5 stars$1.31-0.7%$3.00+128.8%-7.0%$62.74M$659,000.00-1.0670Positive NewsIMMPImmutep1.6822 of 5 stars$1.84-2.1%$8.50+362.0%-20.2%$267.83M$5.14M0.002,021Gap DownPRMEPrime Medicine2.7546 of 5 stars$2.03+4.1%$13.38+558.9%-71.6%$266.26M$2.98M-0.99234Gap DownSLRNAcelyrin3.1919 of 5 stars$2.64-4.0%$9.60+263.6%-61.5%$265.87MN/A-1.07135ANNXAnnexon2.3693 of 5 stars$2.70+12.5%$15.80+485.2%-68.6%$263.30MN/A-2.5760Positive NewsGap DownITOSiTeos Therapeutics2.7174 of 5 stars$6.89+0.1%$25.75+273.7%-53.7%$263.16M$35M-2.1990CDTXCidara Therapeutics4.3554 of 5 stars$23.63+5.2%$39.14+65.6%+21.7%$258.82M$1.28M-0.9390Short Interest ↑ACBAurora Cannabis0.3916 of 5 stars$4.57+2.5%N/A+0.9%$256.14M$320.81M91.421,340News CoverageGap UpTSVT2seventy bio3.0965 of 5 stars$4.96+0.2%$6.67+34.4%-7.5%$255.88M$45.62M-2.67440Earnings ReportShort Interest ↓CRDFCardiff Oncology1.6381 of 5 stars$3.79+1.1%$11.67+207.8%-38.4%$249.47M$683,000.00-4.0320OLMAOlema Pharmaceuticals2.6884 of 5 stars$4.32+2.1%$27.50+536.6%-63.7%$247.53MN/A-1.9770Analyst ForecastGap DownHigh Trading Volume Remove Ads Related Companies and Tools Related Companies IMMP Competitors PRME Competitors SLRN Competitors ANNX Competitors ITOS Competitors CDTX Competitors ACB Competitors TSVT Competitors CRDF Competitors OLMA Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IKNA) was last updated on 3/31/2025 by MarketBeat.com Staff From Our PartnersA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredTrump’s Great Society Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ikena Oncology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ikena Oncology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
